Bladder cancer is the most common urinary system malignancy in the United States and is characterized by its diverse prognosis and high recurrence rate. However, the molecular mechanisms underlying its progression remain unknown. Accumulating evidence suggests a critical role for miRNAs in bladder cancer progression.
In this study, we found that miR-492 expression levels were significantly higher in bladder cancer tissue and the serum of bladder cancer patients by bioinformatics analysis and a panel of clinical samples. The results of receiver operating characteristic curve analysis suggested the potential diagnostic value of serum miR-492 for bladder cancer. In vitro and in vivo functional assays showed that knockdown of miR-492 suppressed proliferation and metastasis of bladder cancer cells. Gap junction beta-4 protein was predicted to be a direct target of miR-492, which was validated using a luciferase reporter assay. Further cellular functional assays showed that suppression of miR-492 abrogated bladder cancer cell proliferation and metastasis by targeting gap junction beta-4 protein.
miR-492 promotes cancer progression by targeting GJB4 and is a novel biomarker for bladder cancer.
OncoTargets and therapy. 2019 Dec 24*** epublish ***
Kai Wang, Hang Lü, Hongchen Qu, Qingpeng Xie, Tao Sun, Ou Gan, Bin Hu
Department of Urology Surgery, Liaoning Province Cancer Hospital and Institute (Cancer Hospital of China Medical University), Shenyang 110004, People's Republic of China.